Sang Tae Noh1, Hyoung Shin Lee2, Soo Jin Lim3, Sung Won Kim2, Hee Kyung Chang4, Junghwan Oh5, Chang-Ho Jeon6, Jong Wook Park7, Kang Dae Lee8. 1. Department of Otolaryngology-Head and Neck Surgery, Kosin University Graduate School, Busan, South Korea. 2. Department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine, 34, Amnam-Dong, Seo-Gu, Busan, 602-715, Republic of Korea. 3. Kosin University College of Medicine, Busan, South Korea. 4. Department of Pathology, Kosin University College of Medicine, Busan, South Korea. 5. Department of Biomedical Engineering, Pukyong National University, Busan, South Korea. 6. Department of Laboratory Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea. 7. Department of Immunology, School of Medicine, Keimyung University, Daegu, South Korea. 8. Department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine, 34, Amnam-Dong, Seo-Gu, Busan, 602-715, Republic of Korea. kdlee59@gmail.com.
Abstract
BACKGROUND: Various subtypes of melanoma-associated antigens (MAGEs) are expressed in the tumor tissues of patients with head and neck squamous cell carcinoma (HNSCC). However, little data are currently available on how the gene expression of MAGEs impacts clinical patterns and oncologic outcomes. We have therefore evaluated the expression of MAGE-A1-6 (A1-6) subtypes in tumor tissues of patients with HNSCC and the clinical impact of this expression. METHODS: This was a retrospective review of 53 patients with histologically proven HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx who underwent both treatment and analysis by reverse transcription (RT)-PCR assay with a common primer to identify the expression of MAGE-A1-6 subtypes in the tumor tissue. The clinicopathologic factors and oncologic outcomes of these patients and the correlations of both to MAGE-A1-6 gene expression were analyzed. RESULTS: MAGE-A1-6 subtypes were expressed in the tumor tissues of 37 patients (69.8 %). Patient age of ≥65 years [p = 0.031, hazard ratio (HR) 4.866] and advanced American Joint Committee on Cancer stage (p = 0.035, HR 4.291) were independent risk factors for expression of MAGE-A1-6 subtypes. Patients with MAGE-A1-6 expression had lower disease-free survival (p = 0.029), disease-specific survival (p = 0.070), and overall survival (p = 0.017) rates. Overall survival rate was independently associated to chemotherapy (p = 0.011, HR 2.859), while no surgery (p = 0.050, HR 2.400) and MAGE-A1-6 expression (p = 0.050, HR 2.527) showed borderline significance. CONCLUSION: In our patient group the expression of MAGE-A1-6 subtypes in tumor tissues of patients with HNSCC was correlated with advanced clinical stage of cancer and poor oncologic outcomes. We suggest that gene expression of MAGE-A1-6 subtypes may be considered to be a predictive factor to determine patient treatment or follow-up strategy.
BACKGROUND: Various subtypes of melanoma-associated antigens (MAGEs) are expressed in the tumor tissues of patients with head and neck squamous cell carcinoma (HNSCC). However, little data are currently available on how the gene expression of MAGEs impacts clinical patterns and oncologic outcomes. We have therefore evaluated the expression of MAGE-A1-6 (A1-6) subtypes in tumor tissues of patients with HNSCC and the clinical impact of this expression. METHODS: This was a retrospective review of 53 patients with histologically proven HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx who underwent both treatment and analysis by reverse transcription (RT)-PCR assay with a common primer to identify the expression of MAGE-A1-6 subtypes in the tumor tissue. The clinicopathologic factors and oncologic outcomes of these patients and the correlations of both to MAGE-A1-6 gene expression were analyzed. RESULTS: MAGE-A1-6 subtypes were expressed in the tumor tissues of 37 patients (69.8 %). Patient age of ≥65 years [p = 0.031, hazard ratio (HR) 4.866] and advanced American Joint Committee on Cancer stage (p = 0.035, HR 4.291) were independent risk factors for expression of MAGE-A1-6 subtypes. Patients with MAGE-A1-6 expression had lower disease-free survival (p = 0.029), disease-specific survival (p = 0.070), and overall survival (p = 0.017) rates. Overall survival rate was independently associated to chemotherapy (p = 0.011, HR 2.859), while no surgery (p = 0.050, HR 2.400) and MAGE-A1-6 expression (p = 0.050, HR 2.527) showed borderline significance. CONCLUSION: In our patient group the expression of MAGE-A1-6 subtypes in tumor tissues of patients with HNSCC was correlated with advanced clinical stage of cancer and poor oncologic outcomes. We suggest that gene expression of MAGE-A1-6 subtypes may be considered to be a predictive factor to determine patient treatment or follow-up strategy.
Entities:
Keywords:
Head and neck cancer; Melanoma-associated antigen; Squamous cell carcinoma
Authors: Stefan Hartmann; Till J Meyer; Roman C Brands; Imme R Haubitz; Christian Linz; Axel Seher; Alexander C Kübler; Urs D A Müller-Richter Journal: Int J Mol Med Date: 2015-04-07 Impact factor: 4.101
Authors: Marija Pastorcic-Grgic; Bozena Sarcevic; Danijel Dosen; Antonio Juretic; Giulio C Spagnoli; Marko Grgic Journal: Head Neck Date: 2010-09 Impact factor: 3.147
Authors: David L A Figueiredo; Rui C M Mamede; Rodrigo Proto-Siqueira; Luciano Neder; Wilson A Silva; Marco A Zago Journal: Head Neck Date: 2006-07 Impact factor: 3.147
Authors: Karen L Reckamp; Jasmine A McQuerry; Isa Mambetsariev; Rebecca Pharaon; Susan E Yost; Jeremy Fricke; Tamara Mirzapoiazova; Raju K Pillai; Ziad Khan; Marwan Fakih; Yuan Yuan; Marianna Koczywas; Erminia Massarelli; Prakash Kulkarni; Sumanta K Pal; Martin Sattler; Andrea Bild; Ravi Salgia Journal: Future Sci OA Date: 2020-11-25
Authors: Adrian von Witzleben; Chuan Wang; Simon Laban; Natalia Savelyeva; Christian H Ottensmeier Journal: Cells Date: 2020-09-15 Impact factor: 6.600